Risk stratification for predicting symptomatic skeletal events (SSEs) in breast cancer patients with bone metastases

Patients with elevated CEA level (>5 ng/mL) and extensive vertebral metastases (≥20) should be closely monitored in routine clinical care, to allow prevention of pathological fracture or paraplegia with the intervention of orthopedists or radiologists.